On Thursday, H.C. Wainwright adjusted its outlook on shares of X4 Pharmaceuticals (NASDAQ: NASDAQ:XFOR), decreasing the 12-month price target to $1.50 from the previous target of $5.00. Despite the reduction, the firm maintained a Buy rating on the stock. The revision follows X4 Pharmaceuticals' third-quarter financial report, which revealed revenues and earnings that diverged from consensus estimates.
X4 Pharmaceuticals announced its third-quarter financial results on Wednesday, reporting total revenue of $0.56 million. This figure fell short of the consensus estimate of $1.69 million. However, the company reported a net income of $0.18 per share, defying the expected net loss of $0.17 per share. These results have prompted H.C. Wainwright to update its financial model for the company.
Looking ahead to the full year of 2024, H.C. Wainwright projects total revenues for X4 Pharmaceuticals to reach $1.9 million, with an anticipated net loss of $0.14 per share. The firm has adjusted its revenue expectations for Xolremdi, X4's drug, projecting it to generate $1.87 million in 2024. This is a significant revision from the initial forecast.
The firm also provided a long-term outlook for Xolremdi, estimating that revenue from the drug will grow to $72.8 million by 2032. The new price target of $1.50 per share reflects these updated projections and the recent financial performance of X4 Pharmaceuticals.
In other recent news, X4 Pharmaceuticals has seen a shift in its financial outlook as Stifel, a financial services firm, lowered its price target for the company to $4.00 from the previous $5.00, while still maintaining a Buy rating. This adjustment is a result of recent observations of X4's product, XOLREMDI's, performance.
Despite high expectations, the sales of XOLREMDI, a treatment for the rare genetic immunodeficiency disorder WHIM syndrome, remained stagnant at $0.6 million in the second quarter of 2024.
Stifel analysts have noted that patient screening and onboarding for XOLREMDI appears slower than expected, which could potentially impact the drug's short-term revenue and the company's financial standing. This is particularly significant as X4 Pharmaceuticals is anticipated to require financial support ahead of the expected year-end 2026 top-line Phase 3 data for chronic neutropenia, another condition for which XOLREMDI is being evaluated.
While Phase 2 data for chronic neutropenia continues to show promise, Stifel's revised price target primarily reflects lower projected revenues from XOLREMDI for the fiscal year 2024 and beyond, as well as updated financing assumptions. These developments highlight the evolving landscape for X4 Pharmaceuticals in the biopharmaceutical market.
InvestingPro Insights
Recent InvestingPro data paints a challenging picture for X4 Pharmaceuticals, aligning with H.C. Wainwright's revised outlook. The company's market capitalization stands at a modest $46.72 million, reflecting investor caution. X4's stock has experienced significant downward pressure, with a striking 55.03% decline in just the past week and a 71.86% drop over the last six months.
InvestingPro Tips highlight that X4 is "quickly burning through cash" and "not profitable over the last twelve months," which corroborates the firm's concerns about the company's financial trajectory. However, it's worth noting that X4 "holds more cash than debt on its balance sheet," potentially providing some financial flexibility as it navigates these challenges.
For investors seeking a more comprehensive analysis, InvestingPro offers 12 additional tips for X4 Pharmaceuticals, providing a deeper understanding of the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.